Stocktoria
iBio, Inc. IBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2008-08-18
iBio, Inc. statistics & valuation
Market cap$83.0M
P / B5.6×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | — | — | — | 38.3% |
| Operating margin | -4650.5% | -7392.9% | — | -1576.3% | -1312.1% |
| Net margin | -4594.2% | -11069.8% | — | -2670.0% | -978.8% |
| FCF margin | -3830.0% | -8339.6% | — | -2378.5% | -1475.5% |
| Return on assets | -79.3% | -86.7% | -157.8% | -50.6% | -15.8% |
| Return on equity | -123.5% | -116.8% | -422.7% | -79.2% | -21.4% |
| Current ratio | 1.59 | 4.08 | 1.19 | 1.48 | 15.74 |
| Revenue growth | 77.8% | — | -100.0% | -20.5% | 44.7% |
Source: SEC EDGAR filings · CIK 0001420720 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.